Nanovibronix (NASDAQ:FEED) Shares Set to Reverse Split on Tuesday, September 1st

Nanovibronix, Inc. (NASDAQ:FEED) shares are going to reverse split on Tuesday, September 1st. The 1-12 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 31st.

Nanovibronix Trading Down 6.4%

FEED traded down $0.02 during trading on Friday, hitting $0.34. The company had a trading volume of 465,195 shares, compared to its average volume of 1,623,298. Nanovibronix has a 1-year low of $0.29 and a 1-year high of $17.40. The business has a 50-day moving average of $0.44 and a 200-day moving average of $1.20.

Nanovibronix (NASDAQ:FEED) last announced its quarterly earnings data on Monday, August 17th. The company reported ($1.98) earnings per share for the quarter. The company had revenue of $0.24 million for the quarter. Nanovibronix had a negative return on equity of 60.73% and a negative net margin of 1,093.61%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on FEED. Wall Street Zen raised shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nanovibronix in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Insider Buying and Selling

In other Nanovibronix news, insider Christian Michael Glibert sold 210,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $0.69, for a total value of $144,900.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.20% of the stock is owned by company insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non?invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low?intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound?care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound?care clinics, long?term care facilities and patients requiring home?based therapies.